What it's for (Indications)
- Ezetimibe + Rosuvastatin Calcium is indicated as an adjunct to diet in patients with primary hyperlipidemia (heterozygous familial and non-familial) to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (ApoB), and non-high-density lipoprotein cholesterol (non-HDL-C), and to increase high-density lipoprotein cholesterol (HDL-C).
- This combination therapy is particularly suitable for patients whose lipid levels are not adequately controlled with rosuvastatin or ezetimibe alone, or for those already receiving both components as separate tablets.
- It is also indicated for the reduction of the risk of cardiovascular events in patients with coronary heart disease (CHD) and a history of acute coronary syndrome (ACS) who are on optimally titrated statin therapy.
- Furthermore, it can be used in patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.
- g.
- , LDL apheresis) or if such treatments are unavailable.
- The comprehensive lipid-modifying effects aim to reduce atherosclerotic plaque progression and subsequent cardiovascular morbidity and mortality, improving overall cardiovascular health outcomes for eligible patients.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended dosage of ezetimibe + rosuvastatin calcium is one tablet orally once daily, with or without food, at any time of the day. The dosage should be individualized based on the patient's baseline LDL-C levels, existing cardiovascular risk factors, and the patient's response to treatment. Available strengths typically combine 10 mg of ezetimibe with varying doses of rosuvastatin (e.g., 5 mg, 10 mg, 20 mg, 40 mg). For patients requiring intensive LDL-C reduction, higher doses may be considered, up to a maximum of 40 mg rosuvastatin combined with 10 mg ezetimibe daily, strictly under medical supervision after careful assessment of risks and benefits. Prior to initiation, and throughout treatment, patients should be placed on a standard cholesterol-lowering diet. Adjustments to the dose should be made at intervals of 4 weeks or more, as necessary, following assessment of lipid profiles. Specific dose modifications are required for patients with severe renal impairment (creatinine clearance < 30 mL/min), where the maximum recommended rosuvastatin dose is 10 mg once daily. Concomitant administration with certain drugs, such as cyclosporine, gemfibrozil, or specific protease inhibitors, necessitates careful dose adjustments and monitoring due to potential increases in rosuvastatin exposure and increased risk of adverse effects. |
Safety & Warnings
Common Side Effects
- The most commonly reported adverse reactions associated with ezetimibe + rosuvastatin calcium include musculoskeletal pain (e.
- g.
- , myalgia, arthralgia), headache, abdominal discomfort (e.
- g.
- , nausea, constipation, diarrhea), fatigue, and influenza-like symptoms.
- While generally well-tolerated, more serious side effects, though less common, warrant immediate medical attention.
- These include myopathy, characterized by muscle pain, tenderness, or weakness accompanied by creatine kinase (CK) elevations greater than ten times the upper limit of normal (ULN), and its severe form, rhabdomyolysis, which can lead to acute renal failure.
- Liver enzyme abnormalities, specifically elevations in serum transaminases (ALT, AST), have been observed; persistent elevations exceeding three times the ULN necessitate discontinuation of therapy and thorough investigation.
- Other potential adverse effects include new-onset diabetes mellitus, particularly in patients with pre-existing risk factors, and rare cases of interstitial lung disease presenting with dyspnea, non-productive cough, and general deterioration of health.
- Hypersensitivity reactions, including rash, pruritus, urticaria, and angioedema, have also been reported.
- Rarely, cognitive impairment such as memory loss, forgetfulness, amnesia, or confusion may occur, which is usually reversible upon discontinuation of statin therapy.
- Patients experiencing any severe or persistent side effects should consult their healthcare provider.
Serious Warnings
- Black Box Warning: **Serious Warnings: Myopathy/Rhabdomyolysis and Hepatotoxicity** While ezetimibe + rosuvastatin calcium does not carry a specific FDA-mandated Black Box Warning, it is crucial for healthcare professionals and patients to be acutely aware of the significant potential for serious adverse effects, primarily myopathy/rhabdomyolysis and hepatotoxicity. These conditions, though rare, can be severe and life-threatening. **Myopathy and Rhabdomyolysis:** Statin components, including rosuvastatin, can cause myopathy, defined as muscle pain, tenderness, or weakness with creatine kinase (CK) elevations typically greater than ten times the upper limit of normal (ULN). Rhabdomyolysis, a more severe and potentially fatal form of myopathy, involves extensive muscle breakdown that can lead to acute renal failure secondary to myoglobinuria. The risk of myopathy/rhabdomyolysis is dose-related for rosuvastatin and is significantly increased by concomitant use of other drugs that can cause myopathy, such as fibric acid derivatives (e.g., gemfibrozil), cyclosporine, specific protease inhibitors, or in patients with advanced age, renal impairment, or uncontrolled hypothyroidism. Patients should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. Therapy should be discontinued immediately if myopathy is diagnosed or strongly suspected, or if CK levels are markedly elevated. **Hepatotoxicity:** Statin therapy has been associated with elevations in serum transaminases (ALT, AST). Although usually transient and not associated with clinical symptoms, persistent elevations exceeding three times the ULN warrant discontinuation of therapy and further investigation for underlying liver injury. Liver function tests should be performed prior to the initiation of treatment and periodically as clinically indicated to monitor for potential hepatic impairment. This product should be used with extreme caution in patients who consume substantial quantities of alcohol or have a history of liver disease, as these factors may predispose them to increased risk of hepatotoxicity. If jaundice, dark urine, or other signs of liver damage occur, the medication should be discontinued immediately and hepatic function thoroughly evaluated.
- Patients receiving ezetimibe + rosuvastatin calcium should be closely monitored for potential serious adverse reactions.
- The most significant concern involves myopathy and rhabdomyolysis, a potentially life-threatening condition.
- The risk of myopathy is dose-related for rosuvastatin and is increased by concomitant use of other drugs that can cause myopathy (e.
- g.
- , fibric acid derivatives like gemfibrozil), cyclosporine, specific protease inhibitors, or in patients with advanced age, renal impairment, or uncontrolled hypothyroidism.
- Patients should be advised to report any unexplained muscle pain, tenderness, or weakness immediately.
- Treatment should be discontinued if myopathy is diagnosed or suspected.
- Liver function tests (LFTs) should be performed prior to initiation of therapy and periodically thereafter, or as clinically indicated.
- Persistent elevations in serum transaminases (>3 times ULN) indicate significant hepatotoxicity and require discontinuation of the medication.
- Cases of new-onset diabetes mellitus have been reported with statin use, and patients at high risk should be monitored clinically and biochemically.
- Rare instances of interstitial lung disease have occurred; patients developing dyspnea, non-productive cough, and constitutional symptoms should be evaluated.
- Caution is advised in patients consuming substantial quantities of alcohol or who have a history of liver disease.
- Pregnancy and lactation are contraindications, as statins may cause fetal harm and are excreted in breast milk.
- Furthermore, the maximum recommended dose of rosuvastatin 40 mg is contraindicated in patients with predisposing factors for myopathy/rhabdomyolysis, including severe renal impairment.
How it Works (Mechanism of Action)
Ezetimibe + Rosuvastatin Calcium combines two distinct lipid-lowering agents with complementary mechanisms of action, leading to a synergistic reduction in elevated cholesterol levels. Rosuvastatin, an HMG-CoA reductase inhibitor, functions by competitively blocking the enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase in the liver. This enzyme is rate-limiting in the mevalonate pathway, which is responsible for endogenous cholesterol biosynthesis. By inhibiting cholesterol synthesis, rosuvastatin prompts hepatocytes to upregulate the expression of low-density lipoprotein (LDL) receptors on their surfaces, thereby increasing the cellular uptake and catabolism of circulating LDL-cholesterol. This action significantly reduces plasma LDL-C levels, as well as total cholesterol, non-HDL-C, and triglycerides, while modestly increasing high-density lipoprotein cholesterol (HDL-C). Ezetimibe acts by inhibiting the absorption of dietary and biliary cholesterol from the small intestine without affecting the absorption of fat-soluble vitamins, triglycerides, or bile acids. It targets the Niemann-Pick C1-Like 1 (NPC1L1) protein, a key transporter responsible for cholesterol absorption at the brush border of enterocytes. By reducing the delivery of intestinal cholesterol to the liver, ezetimibe further depletes hepatic cholesterol stores. This, in turn, also enhances LDL receptor activity, similar to statins, but through a different primary mechanism, resulting in a synergistic lipid-lowering effect when combined with rosuvastatin, optimizing cholesterol reduction and cardiovascular risk mitigation.